Canopy Growth (CGC) Other Non Operating Income (2019 - 2026)
Canopy Growth (CGC) posted Other Non Operating Income of -$29.7 million for Q4 2025, down 437.17% sequentially from $8.8 million in Q3 2025, and up 43.86% YoY from -$20.7 million in Q4 2024.
Canopy Growth (CGC) Other Non Operating Income (2019 - 2026) Analysis & Trends
Canopy Growth has reported Other Non Operating Income for 7 years, with the latest figure at -$29.7 million in Q4 2025.
- Quarterly Other Non Operating Income rose 43.86% year-over-year to -$29.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$89.7 million (down 598.01% YoY) and the FY2026 annual result came in at -$1.1 million, up 99.59% from the prior year.
- Other Non Operating Income slipped to -$29.7 million in Q4 2025 per CGC's latest filing, from $8.8 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $172.4 million in Q1 2024 and troughed at -$646.8 million in Q1 2022.
- A 5-year average of -$52.0 million and a median of -$15.8 million in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Other Non Operating Income plunged 141034.7% in 2022, then surged 8409.42% in 2024.
- Over 5 years, Other Non Operating Income stood at $785402.7 in 2021, then plunged by 10932.89% to -$85.1 million in 2022, then tumbled by 38.05% to -$117.5 million in 2023, then jumped by 54.93% to -$52.9 million in 2024, then soared by 43.86% to -$29.7 million in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$29.7 million, $8.8 million, and -$15.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Canopy Growth | 439.15 Mn | 192.14 Mn | 16.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.35 Mn |
| Dec 31, 2025 | -29.72 Mn |
| Sep 30, 2025 | 8.81 Mn |
| Jun 30, 2025 | -15.84 Mn |
| Dec 31, 2024 | -52.93 Mn |
| Sep 30, 2024 | -48.36 Mn |
| Jun 30, 2024 | -53.10 Mn |
| Mar 31, 2024 | 172.40 Mn |
| Dec 31, 2023 | -117.46 Mn |
| Sep 30, 2023 | -89.30 Mn |
| Jun 30, 2023 | -103,478.89 |
| Mar 31, 2023 | 2.03 Mn |
| Dec 31, 2022 | -85.08 Mn |
| Sep 30, 2022 | -29.96 Mn |
| Jun 30, 2022 | -3.87 Mn |
| Mar 31, 2022 | -646.76 Mn |
| Dec 31, 2021 | 785,402.72 |
| Sep 30, 2021 | 700,669.01 |
| Jun 30, 2021 | 837,932.97 |
| Mar 31, 2021 | -458,257.49 |